
Please try another search
Fountain Biopharma Inc. develops therapeutic monoclonal antibodies for cancer and immunological conditions. Its products under clinical stage comprises FB825 for treating atopic dermatitis, allergic rhinitis, and other allergic diseases; FB317 to treat severe asthma and allergy-associated diseases; and FB704A for the treatment of rheumatoid arthritis, oncological diseases, and cytokine storms. Its products include SNA01, SNA02, and SNA03 that are under preclinical stage for the treatment of cancer. Fountain Biopharma Inc. was founded in 2010 and is based in Taipei, Taiwan. Fountain Biopharma Inc. is a subsidiary of Microbio Co., Ltd.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review